A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites

Summary

Malignant ascites is a severe complication of many types of human cancer. Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant ascites. Therefore, drugs such as apatinib that target angiogenesis may control the development of malignant ascites. The study is to evaluate the efficacy and safety of apatinib in patients with refractory malignant ascites.

Timeline

Start

2017-01

Primary completion

2018-12

Completion

2019-12

Drugs

Indications